Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIS793 (± spartalizumab) plus gemcitabine + nab-paclitaxel vs gemcitabine + nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma
2020-000349-14Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nisevokitug in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PDAC) (3 arms), sponsored by Novartis. Primary endpoint: Safety run-in primary endpoint. Started Jul 2020; status: terminated.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2020-000349-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000349-14.